Production (Stage)
Aldeyra Therapeutics, Inc.
ALDX
$2.22
-$0.03-1.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -22.86% | -232.61% | -84.60% | -87.47% | 48.24% |
| Total Depreciation and Amortization | 0.50% | -3.16% | -3.08% | -4.20% | -9.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.11% | 215.41% | 211.21% | -13.50% | -66.34% |
| Change in Net Operating Assets | -40.27% | -51.57% | 648.12% | 134.60% | -283.85% |
| Cash from Operations | -25.04% | -2,505.44% | 0.62% | 1.00% | -5.60% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 124.00% | -- | -- | -- | -201.26% |
| Cash from Investing | 124.00% | -- | -- | -- | -201.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 71.94% | -- | -- | -- |
| Issuance of Common Stock | 5,409.89% | 1,059.93% | -90.84% | -100.00% | -65.40% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5,409.89% | 100.77% | 37.49% | -100.00% | -65.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 89.64% | -2,555.38% | 65.11% | -135.63% | -295.70% |